Pharming Group company profile
Company profile
Pharming Group has 407 employees and is headquartered in Leiden, Netherlands.
Pharming Group N.V. develops and commercializes protein replacement therapies and precision medicines for rare diseases, with commercial activity in the United States, Europe and other markets worldwide. Its lead product is RUCONEST, a treatment for acute attacks of hereditary angioedema in adults and adolescents. Joenja, an oral medicine for activated phosphoinositide 3-kinase delta syndrome, is the other principal product, and the company continues to develop it alongside a partnership with Novartis.
In the fiscal year ended December 2025, revenue reached USD 376.1 million, up 26.6% on the previous year, while net profit stood at USD 2.9 million. The company had 407 employees and is headquartered in Leiden, the Netherlands, where it was incorporated in 1988.
Company facts
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Netherlands
- Headquarters
- Darwinweg 24, 2333 CR, Leiden
- Employees
- 407
- Chief executive
- Fabrice Chouraqui
- Founded
- 1988
- Fiscal year
- January - December
- Listing
- PHARM · Euronext Amsterdam
- Currency
- EUR
- ISIN
- NL0010391025
- Website
- pharming.com
Pharming Group and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| Pharming GroupPHARM | Netherlands | $841.25M | 407 | 12.8% | 36.1 |
| InventivaIVA | France | $890.8M | 87 | -5,980.9% | — |
| PhilogenPHIL | Italy | $905.96M | 230 | 79.1% | 3.67 |
| Basilea PharmaceuticaBSLN | Switzerland | $1.07B | 200 | 24.2% | 18.1 |
| GubraGUBRA | Denmark | $730.02M | 330 | -73.1% | — |
| Pharma MarPHM | Spain | $1.1B | 505 | 21.3% | 14.7 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
